<table id="id_1ddc54ce-7ec8-4bc2-b509-502282d9cbff" width="576.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_fcb6fcfb-8ca6-44bb-9157-b873bea71a59">TABLE 2: Effect of SINGULAIR on Asthma-Related Outcome Measurements (Combined Analyses - U.S. and Multinational Trials)</caption>
<col width="50.0%"></col>
<col width="25.0%"></col>
<col align="center" width="25.0%"></col>
<thead>
<tr id="id_b342c43c-2c1e-4f2d-a64a-76153438a5ea">
<td align="left" stylecode="Botrule" valign="top"></td>
<td align="center" stylecode="Botrule" valign="top">SINGULAIR </td>
<td align="center" stylecode="Botrule" valign="top">Placebo </td>
</tr>
</thead>
<tbody>
<tr id="id_56d7d996-109b-43bc-8df1-eccd7646aac0">
<td align="left" stylecode="Toprule" valign="top">Asthma Attack<footnote id="id-cc981de4-7e55-4e73-8a63-c967d9ede526">Asthma Attack defined as utilization of health-care resources such as an unscheduled visit to a doctor's office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</footnote> (% of patients) </td>
<td align="center" stylecode="Toprule" valign="top">11.6 <footnote id="id-b0a0c5fa-ec5c-4aa9-943b-c02449a83772">p&lt;0.001, compared with placebo</footnote>
</td>
<td align="center" valign="top">18.4 </td>
</tr>
<tr id="id_4e4db60a-6b68-4698-a22d-106f344fc145">
<td align="left" valign="top">Oral Corticosteroid Rescue (% of patients) </td>
<td align="center" valign="top">10.7<footnoteref idref="id-b0a0c5fa-ec5c-4aa9-943b-c02449a83772"></footnoteref>
</td>
<td align="center" valign="top">17.5 </td>
</tr>
<tr id="id_257c430a-80cd-426a-9807-d18f4cda5a78">
<td align="left" valign="top">Discontinuation Due to Asthma (% of patients) </td>
<td align="center" valign="top">1.4<footnote id="id-822bc2b9-57ef-498a-8266-78a17f8ef544">p&lt;0.01, compared with placebo</footnote>
</td>
<td align="center" valign="top">4.0 </td>
</tr>
<tr id="id_4e1e4268-131f-4da4-836d-5200f6f61229">
<td align="left" valign="top">Asthma Exacerbations<footnote id="id-918ffd5f-0189-4369-8a63-595691b022cc">Asthma Exacerbation defined by specific clinically important decreases in PEFR, increase in β-agonist use, increases in day or nighttime symptoms, or the occurrence of an asthma attack.</footnote> (% of days)</td>
<td align="center" valign="top">12.8<footnoteref idref="id-b0a0c5fa-ec5c-4aa9-943b-c02449a83772"></footnoteref>
</td>
<td align="center" valign="top">20.5 </td>
</tr>
<tr id="id_d0c177d2-a32a-4f1a-a31d-4ce314f99325">
<td align="left" valign="top">Asthma Control Days<footnote id="id-a11241dd-8216-4ff1-85da-a4757cc6a57f">An Asthma Control Day defined as a day without any of the following: nocturnal awakening, use of more than 2 puffs of β-agonist, or an asthma attack.</footnote> (% of days) </td>
<td align="center" valign="top">38.5<footnoteref idref="id-b0a0c5fa-ec5c-4aa9-943b-c02449a83772"></footnoteref>
</td>
<td align="center" valign="top">27.2 </td>
</tr>
<tr id="id_d431615c-fa2c-49f5-be34-8fab5fdb2692">
<td align="left" valign="top">Physicians’ Global Evaluation (score)<footnote id="id-8e63ad97-ab3d-4724-b30c-af2ac0e12cb6">Physicians’ evaluation of the patient’s asthma, ranging from 0 to 6 (“very much better” through “very much worse”, respectively). </footnote>
</td>
<td align="center" valign="top">1.77<footnoteref idref="id-b0a0c5fa-ec5c-4aa9-943b-c02449a83772"></footnoteref>
</td>
<td align="center" valign="top">2.43</td>
</tr>
<tr id="id_6712a7ba-28c0-4d32-8d4d-256fbe233d16">
<td align="left" stylecode="Botrule" valign="top">Patients’ Global Evaluation (score)<footnote id="id-e5c4caae-641d-47ca-ad1c-7a5b33126683">Patients’ evaluation of asthma, ranging from 0 to 6 (“very much better” through “very much worse”, respectively).</footnote>
</td>
<td align="center" stylecode="Botrule" valign="top">1.60<footnoteref idref="id-b0a0c5fa-ec5c-4aa9-943b-c02449a83772"></footnoteref>
</td>
<td align="center" stylecode="Botrule" valign="top"> 2.15</td>
</tr>
</tbody>
</table>